The FDA has even authorised a drug manufactured with cannabidiol for that goal (Epidiolex). However the agency only suggests it for two unusual varieties of childhood epilepsy named Lennox-Gastaut syndrome and Dravet syndrome.Supplied these linked genetic and environmental vulnerabilities, additional facts from possible, longitudinal investigation